查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880424

高血鉀治療市場預測至2032年：按藥物類型、給藥途徑、通路、適應症、最終用戶和地區分類的全球分析

Hyperkalemia Drugs Market Forecasts to 2032 - Global Analysis By Drug Type, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球高血鉀治療市場價值將達到 14.2 億美元，到 2032 年將達到 39.7 億美元，在預測期內的複合年成長率為 15.8%。

高血鉀藥物旨在降低異常高的血鉀水平，過高的血鉀會干擾正常的心臟活動並帶來嚴重的健康風險。這些治療方法透過以下方式發揮作用：將鉀離子重新帶回細胞內，促進排放透過尿液和消化器官系統排出體外，或在腸道內與鉀離子結合以限制其吸收。常用的治療方法包括利尿劑、葡萄糖胰島素、磺酸鹽磺酸鈉和新型鉀結合劑。這些藥物在恢復安全的血鉀平衡和保護患者免受危險的心臟併發症發揮著至關重要的作用。

RAAS抑制劑的使用日益增多

由於這些藥物會升高血鉀水平，臨床醫生越來越依賴鉀粘合劑來維持電解質平衡。治療監測工具和電子處方平台的進步也促進了鉀結合劑的更廣泛應用。新的臨床指引建議長期使用腎素-血管張力素-醛固酮系統（RAAS）抑制劑，間接凸顯了有效管理高血鉀的必要性。新興的數位化依從性技術使得高血鉀藥物與RAAS抑制劑合併用藥更加安全。隨著精準醫療的進步，針對個人風險狀況量身定做的聯合治療策略在臨床實踐中日益普及。

患者依從性挑戰

許多鉀粘合劑需要特定的給藥方案，這可能導致長期依從性較低。儘管出現了每日一次給藥和易於吞嚥的粉劑等新劑型，但維持患者的持續用藥仍然是一項挑戰。數位健康工具，例如提醒應用程式和自動追蹤系統，正在興起以解決依從性問題。然而，即使有了技術支持，生活方式的限制和胃腸道副作用也會阻礙規律用藥。此外，某些地區病患教育不足也減緩了先進高血鉀治療方法的普及。

整合數位健康和​​個人化醫療

遠端監測平台能夠持續追蹤血鉀水平，使臨床醫師能夠快速調整治療方案。基於人工智慧的風險評估工具能夠更準確地預測高血鉀的發生，從而支持預防性治療策略。製藥公司正與數位醫療Start-Ups合作，開發整合式醫療服務路徑。包括藥物基因組學分析在內的個人化醫療策略，正在改善藥物選擇和治療反應。這些技術和治療方法的融合，為市場快速創新和提高患者參與度奠定了基礎。

價格壓力與報銷政策變化

衛生部門正日益關注慢性鉀結合劑治療的成本效益。學名藥競爭加劇，對價格較高的品牌藥帶來壓力。與真實世界療效掛鉤的新型報銷模式要求企業證明其產品具有持續的臨床療效。在關鍵市場，以技術主導的衛生經濟評估正成為支付方決策的核心。如果沒有適應性定價策略，製造商在對價格敏感的地區可能會面臨進入限制。

新冠疫情的感染疾病：

供應鏈中斷影響了多個地區的藥品供應。然而，新冠疫情加速了遠端醫療的普及，並改善了弱勢患者的遠端醫療管理。電子處方箋和虛擬諮詢增強了封鎖期間的醫療服務連續性。監管機構推出了臨時性靈活措施，加快了更新配方和給藥系統的核准。疫情後，醫療系統正優先發展以數位化為先導的照護模式和針對慢性病（包括高血鉀）的去中心化治療管道。

預計在預測期內，聚苯乙烯磺酸鹽（SPS）細分市場將佔據最大的市場佔有率。

由於聚苯乙烯磺酸鹽（SPS）具有悠久的臨床應用歷史和良好的成本效益，預計在預測期內，SPS仍將佔據最大的市場佔有率。其在醫院和零售藥局的廣泛供應持續支撐著強勁的需求。近期研發的改進提升了粉末製劑的性能，簡化了給藥方法，進一步擴大了其應用範圍。 SPS是醫療專業人員熟悉的藥物，因此常用於緊急情況。儘管出現了新的替代藥物，但由於其價格實惠，SPS在發展中國家仍然是首選。

預計在預測期內，居家醫療環境領域將呈現最高的複合年成長率。

預計在預測期內，居家醫療保健領域將實現最高成長率，這主要得益於慢性病管理在醫院外的興起。遠端監測設備的廣泛應用使高血鉀的居家管理更加安全。新型攜帶式鉀結合劑和易於服用的製劑也提高了居家照護的接受度。遠端醫療的整合使醫生無需面對面會診即可調整劑量。成本節約和便利性促使患者更傾向於選擇居家照護而非傳統的臨床照護。

佔比最大的地區：

由於糖尿病、腎臟病和心血管疾病患者人數不斷增加，預計亞太地區將在預測期內佔據最大的市場佔有率。醫療基礎設施的快速發展正在改善高血鉀先進治療的可近性。中國、印度和日本政府正在推動國內藥品生產和數位醫療整合。行動醫療技術的應用正在改善醫療服務的連續性和鉀監測的準確性。對基於人工智慧的診斷平台的投資不斷成長，正在加速電解質異常的早期檢測。

複合年成長率最高的地區：

在預測期內，由於強勁的技術進步和高階高血鉀治療方法的早期應用，北美預計將實現最高的複合年成長率。該地區強大的研發生態系統支持鉀結合劑和數位治療工具的持續創新。醫療服務提供者正在整合以人工智慧為基礎的監測系統，以最佳化慢性病管理。有利的報銷機制使患者更容易獲得新型高效的療法。遠距遠端醫療和連網設備的日益普及正在促進高血鉀的主動管理。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算、預測和複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球高血鉀治療市場（依藥物類型分類）

  • 介紹
  • 磺酸鹽磺酸鈉（SPS）
  • 帕蒂·羅梅爾
  • 環矽酸鋯鈉
  • 磺酸鹽磺酸鈣
  • 其他藥物類型

6. 全球高血鉀治療市場（依給藥途徑分類）

  • 介紹
  • 口服
  • 靜脈

7. 全球高血鉀治療市場（依通路）

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 網路藥房

8. 全球高血鉀治療市場（依適應症分類）

  • 介紹
  • 急性高血鉀
  • 慢性高血鉀症
  • 其他跡象

9. 全球高血鉀治療市場（以最終用戶分類）

  • 介紹
  • 醫院
  • 診所
  • 門診手術中心
  • 居家照護機構
  • 其他最終用戶

第10章 全球高血鉀治療市場（按地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • AstraZeneca
  • CMP Pharma
  • Vifor Pharma
  • Keryx Biopharmaceuticals
  • Sanofi
  • OPKO Health
  • Perrigo Company plc
  • Viatris
  • Ardelyx
  • Fresenius Kabi
  • Baxter International
  • scPharmaceuticals
  • Pfizer
  • Camber Pharmaceuticals
  • Teva Pharmaceutical Industries
Product Code: SMRC32556

According to Stratistics MRC, the Global Hyperkalemia Drugs Market is accounted for $1.42 billion in 2025 and is expected to reach $3.97 billion by 2032 growing at a CAGR of 15.8% during the forecast period. Hyperkalemia drugs are medications designed to reduce abnormally high potassium levels, which can impair normal heart activity and pose severe health risks. These therapies act by moving potassium back into cells, promoting its removal through urine or the digestive system, or binding it within the gut to limit absorption. Frequently used treatments include diuretics, glucose-assisted insulin, sodium polystyrene sulfonate, and modern potassium-binding formulations. Such drugs play a critical role in restoring safe potassium balance and protecting patients from dangerous cardiac complications.

Market Dynamics:

Driver:

Increased use of RAAS inhibitors

As these drugs elevate potassium levels, clinicians increasingly rely on potassium binders to maintain electrolyte balance. Advancements in therapeutic monitoring tools and e-prescription platforms are supporting wider prescribing confidence. New clinical guidelines promoting long-term RAAS inhibitor use are indirectly amplifying the need for effective hyperkalemia management. Emerging digital adherence technologies are ensuring safer co-administration of hyperkalemia drugs with RAAS inhibitors. With precision medicine growing, combination strategies tailored to individual risk profiles are becoming more common in clinical practice.

Restraint:

Challenges with patient compliance

Many potassium binders require specific dosing schedules, which can reduce long-term compliance. Although new formulations like once-daily or palatable powders are being introduced, consistent patient engagement remains difficult. Digital health tools such as reminder apps and automated follow-up systems are emerging to address adherence gaps. Even with technological support, lifestyle restrictions and gastrointestinal side effects still deter regular use. Limited patient education in some regions also slows the adoption of advanced hyperkalemia therapies.

Opportunity:

Integration of digital health and personalized medicine

Remote monitoring platforms are enabling continuous potassium level tracking, helping clinicians make quicker adjustments to therapy. AI-based risk assessment tools are predicting hyperkalemia episodes more accurately, supporting preventive treatment approaches. Pharmaceutical companies are collaborating with digital health startups to develop integrated care pathways. Personalized medicine strategies, including pharmacogenomic profiling, are improving drug selection and treatment response. This convergence of technology and therapeutics is positioning the market for rapid innovation and expanded patient engagement.

Threat:

Pricing pressure and reimbursement changes

Health authorities are increasingly reviewing the cost-effectiveness of chronic potassium binder therapy. Generic competition is rising, intensifying the pressure on premium-priced branded products. New reimbursement models tied to real-world outcomes are challenging companies to demonstrate consistent clinical benefits. Technology-driven health economic evaluations are becoming central to payer decisions across major markets. Without adaptive pricing strategies, manufacturers may face limited access in cost-sensitive regions.

Covid-19 Impact:

Supply chain interruptions affected drug availability in several regions. However, COVID-19 accelerated telehealth adoption, improving remote treatment oversight for vulnerable patients. Digital prescribing and virtual consultations enhanced continuity of care during lockdowns. Regulatory agencies introduced temporary flexibilities that allowed faster approval of updated formulations and delivery systems. Post-pandemic, health systems are prioritizing digital-first care models and decentralized treatment channels for chronic conditions including hyperkalemia.

The sodium polystyrene sulfonate (SPS) segment is expected to be the largest during the forecast period

The sodium polystyrene sulfonate (SPS) segment is expected to account for the largest market share during the forecast period, due to its long-standing clinical use and cost-effectiveness. Its wide availability across hospitals and retail pharmacies continues to support strong demand. Recent developments in improved powder formulations and easier administration methods are reinforcing its adoption. SPS is frequently utilized in emergency settings due to its familiarity among practitioners. Despite emerging alternatives, its affordability makes it the preferred choice in developing markets.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate, due to increasingly manage chronic disorders outside hospital environments. Growing adoption of remote monitoring devices is enabling safer home-based hyperkalemia management. New portable potassium binders and easy-to-consume formulations are boosting acceptance in home-based care. Telehealth integration is allowing physicians to adjust dosing without requiring in-person visits. Cost savings and convenience are driving patient preference toward home care over traditional clinical settings.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to its expanding population of patients with diabetes, kidney disorders, and cardiovascular conditions. Rapid healthcare infrastructure development is enhancing access to advanced hyperkalemia treatments. Governments across China, India, and Japan are promoting domestic drug manufacturing and digital health integration. Adoption of mobile health technologies is improving treatment continuity and potassium monitoring. Growing investments in AI-based diagnostic platforms are accelerating early detection of electrolyte disorders.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong technological advancements and early adoption of premium hyperkalemia therapies. The region's robust R&D ecosystem supports continuous innovation in potassium binders and digital therapeutic tools. Healthcare providers are integrating AI-based monitoring systems to optimize chronic condition management. Favourable reimbursement structures are accelerating patient access to newer, high-efficacy treatments. Increasing use of telemedicine and connected devices is enhancing proactive hyperkalemia control.

Key players in the market

Some of the key players in Hyperkalemia Drugs Market include AstraZeneca, CMP Pharma, Vifor Pharma, Keryx Biopharma, Sanofi, OPKO Health, Perrigo Co, Viatris, Ardelyx, Fresenius, Baxter International, scPharmaceuticals, Pfizer, Camber Pharma, and Teva Pharma.

Key Developments:

In July 2025, Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.

In June 2022, CMP Pharma announced that Norliqva(R) (Amlodipine) Oral Solution, 1 mg/mL, the first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, is now available. Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.

Drug Types Covered:

  • Sodium Polystyrene Sulfonate (SPS)
  • Patiromer
  • Sodium Zirconium Cyclosilicate
  • Calcium Polystyrene Sulfonate
  • Other Drug Types

Route of Administrations Covered:

  • Oral
  • Intravenous

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Acute Hyperkalemia
  • Chronic Hyperkalemia
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyperkalemia Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Sodium Polystyrene Sulfonate (SPS)
  • 5.3 Patiromer
  • 5.4 Sodium Zirconium Cyclosilicate
  • 5.5 Calcium Polystyrene Sulfonate
  • 5.6 Other Drug Types

6 Global Hyperkalemia Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Intravenous

7 Global Hyperkalemia Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Hyperkalemia Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Acute Hyperkalemia
  • 8.3 Chronic Hyperkalemia
  • 8.4 Other Applications

9 Global Hyperkalemia Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Home Care Settings
  • 9.6 Other End Users

10 Global Hyperkalemia Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 CMP Pharma
  • 12.3 Vifor Pharma
  • 12.4 Keryx Biopharmaceuticals
  • 12.5 Sanofi
  • 12.6 OPKO Health
  • 12.7 Perrigo Company plc
  • 12.8 Viatris
  • 12.9 Ardelyx
  • 12.10 Fresenius Kabi
  • 12.11 Baxter International
  • 12.12 scPharmaceuticals
  • 12.13 Pfizer
  • 12.14 Camber Pharmaceuticals
  • 12.15 Teva Pharmaceutical Industries

List of Tables

  • Table 1 Global Hyperkalemia Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Hyperkalemia Drugs Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 3 Global Hyperkalemia Drugs Market Outlook, By Sodium Polystyrene Sulfonate (SPS) (2024-2032) ($MN)
  • Table 4 Global Hyperkalemia Drugs Market Outlook, By Patiromer (2024-2032) ($MN)
  • Table 5 Global Hyperkalemia Drugs Market Outlook, By Sodium Zirconium Cyclosilicate (2024-2032) ($MN)
  • Table 6 Global Hyperkalemia Drugs Market Outlook, By Calcium Polystyrene Sulfonate (2024-2032) ($MN)
  • Table 7 Global Hyperkalemia Drugs Market Outlook, By Other Drug Types (2024-2032) ($MN)
  • Table 8 Global Hyperkalemia Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 9 Global Hyperkalemia Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 10 Global Hyperkalemia Drugs Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 11 Global Hyperkalemia Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 12 Global Hyperkalemia Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 13 Global Hyperkalemia Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 14 Global Hyperkalemia Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 15 Global Hyperkalemia Drugs Market Outlook, By Application (2024-2032) ($MN)
  • Table 16 Global Hyperkalemia Drugs Market Outlook, By Acute Hyperkalemia (2024-2032) ($MN)
  • Table 17 Global Hyperkalemia Drugs Market Outlook, By Chronic Hyperkalemia (2024-2032) ($MN)
  • Table 18 Global Hyperkalemia Drugs Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 19 Global Hyperkalemia Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Hyperkalemia Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Hyperkalemia Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 22 Global Hyperkalemia Drugs Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 23 Global Hyperkalemia Drugs Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 24 Global Hyperkalemia Drugs Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.